LEVERKUSEN (dpa-AFX) - WuXi Biologics Germany GmbH will take over the operations of one of Bayer's final drug product manufacturing plants in Leverkusen, Germany, and purchase the associated equipment, in combination with a long-term lease contract for the building. Financial details were not disclosed.
The plant would be operated by WuXi Biologics and serve as a back-up site for the final product manufacturing of Kovaltry, an antihemophilic factor.
The transaction is expected to be concluded in the coming months subject to the satisfaction of customary closing conditions.
Copyright RTT News/dpa-AFX
© 2020 AFX News
